AlgoTherapeutix Completes Phase 2 Trial for Neuropathic Pain Therapy

AlgoTherapeutix (AlgoTx) has successfully completed its Phase 2 clinical trial (ACT) for ATX01, a first-in-class, non-opioid treatment for chemotherapy-induced peripheral neuropathy (CIPN). Conducted under Professor Guido Cavaletti, the trial enrolled 276 patients across multiple international sites, evaluating two ATX01 concentrations against placebo.

ATX01 is designed to selectively target nociceptive sodium channels in the peripheral nervous system, alleviating pain with minimal systemic exposure. Results indicated promising efficacy, particularly with the higher 15% concentration. However, high placebo responses in certain study sites impacted overall statistical separation. Post-hoc analysis in low-placebo sites suggests ATX01 15% holds strong therapeutic potential, warranting further clinical development.